Aakash Gupta1, Michael Markl1,2, Bradley Allen1, Lubna Choudhury3, James Carr1,2,3, Robert Bonow3, and Jeremy Collins1
1Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States, 2Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Chicago, IL, United States, 3Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States
Synopsis
4D flow MRI supports
the development of novel energetic biomarkers in hypertrophic cardiomyopathy
(HCM) –
a disease marked by dynamic left ventricular outflow tract obstruction with
mitral regurgitation (MR). We compared kinetic energy and velocity metrics between
obstructive and non-obstructive HCM subtypes to determine where in the left
heart high kinetic energy and flows were generated. Left atrium showed
significantly higher systolic kinetic energy and velocities throughout ventricular
systole due to MR. Including these energetic parameters may be useful to detect
significant MR that is underestimated by echo, identify patients at higher risk
of atrial fibrillation, and inform treatment options.
Introduction
Hypertrophic cardiomyopathy (HCM) has a
prevalence of 1 in 500 (0.2%) and is an important cause of arrhythmic sudden cardiac
death, heart failure, and stroke.1
HCM is a disease marked by unexplained left ventricular hypertrophy.2,3 The most common phenotype, asymmetric septal, is divided
into non-obstructive and obstructive subtypes. Non-obstructive HCM maintains
laminar left ventricular outflow tract (LVOT) flow during systolic ejection
with some flow acceleration.4 However, obstructive HCM
characteristically has narrowed LVOT lumen, systolic anterior motion of the anterior
mitral leaflet, and mitral regurgitation (MR), resulting in complex changes in left
atrial (LA), left ventricular (LV and LVOT) hemodynamics. Current diagnostic
tools are insufficient to fully characterize and quantify abnormalities
associated with HCM. Cardiac 4D flow MRI allows for the measurement of time-resolved
3D cardiac blood flow with full coverage of the LA, LV and LVOT and subsequent
quantification of energy biomarkers. The aim of this feasibility study was to
employ 4D flow MRI for the comprehensive assessment of the effects of HCM on
left-sided cardiac 4D (3D+time) hemodynamics in both non-obstructive and
obstructive HCM.Methods
We studied a cohort of
consecutively recruited patients with asymmetric septal HCM (n=18) using
criteria of interventricular septum thickness of ≥1.5 cm, or ≥1.3 cm for those
with familial HCM (Table 1). Patients were divided into non-obstructive HCM (n=9)
and obstructive HCM (n=9) based on peak LVOT velocity <2 m/s or ≥2 m/s,
respectively. Time-resolved 3D phase-contrast MRI with three-dimensional
velocity encoding (4D flow MRI) captured the LVOT, LV, and LA. Data
preprocessing included noise filtering and correction for Maxwell terms, eddy
currents, and velocity aliasing.5 3D segmentations of the left heart
were performed using commercial software (Mimics, Materialise, Belgium). Further
segmentation into LVOT, LV, and LA was done by plotting velocity MIPs in systole
to identify the high velocity LVOT and approximate position of the mitral valve
using custom software (Matlab, MathWorks, Natick, MA). For each voxel in each
chamber per time point, velocity and kinetic energy (KE) were calculated using
KE=1/2mv2, where velocity (v) came from 4D flow MRI and mass (m) from
multiplying voxel volume by blood density (1.05 g/mL). Energy biomarkers were
derived for each chamber: peak systolic and diastolic velocity (velocitysys,peak
and velocitydiast,peak), standard deviation of chamber velocities
(SDvelocity), and total KE normalized to chamber volume in systole
and diastole (KEsys,norm and KEdiast,norm). To
compare time-resolved average velocity and total KE normalized by chamber
volume (KEnorm) between patients, each patient’s velocities and KE were
interpolated to the highest temporal resolution using a spline. Energy biomarkers
were statistically compared using one-tailed t-tests (alpha=0.05) under the
hypothesis that obstructive HCM has higher velocity and KE.Results
Patient
demographics are summarized in Table 1. Age was significantly different between
the two subgroups (p=0.04). High velocity and MR severity, characteristic of
obstructive HCM, explain increases in peak LVOT velocity and severity of MR (Table
1). Figure 1A depicts laminar LVOT flow seen in a patient with non-obstructive
HCM, while Figure 1C displays disrupted LVOT outflow and MR seen in obstructive
HCM. For energy parameters (Table 1),
obstructive HCM had higher LVOT velocitysys,peak (2.29±0.43 vs.
3.60±0.65 m/s, p<0.001) and velocitydiast,peak (1.75±0.65 vs.
2.46±1.75 m/s, p=0.01) with higher SDvelocity (0.33±0.05 vs.
0.39±0.06 m/s, p=0.04). In the LA, high velocity systolic MR jets in
obstructive HCM created elevated velocitysys,peak (1.62±0.65 vs.
2.41±0.85 m/s, p=0.02), SDvelocity (0.09±0.02 vs. 0.12±0.03 m/s,
p=0.03), and KEsys,norm (0.21±0.08 vs. 0.34±0.15 mJ/mL, p=0.01). KEsys,norm
and KEdiast,norm are depicted as box plots for each chamber (Figure 2).
LVOT average velocities and KEnorm were similar between subgroups
throughout the cardiac cycle (Figures 3-4). LV velocities and KEnorm
were significantly higher in obstructive patients at two time points at the
onset and two near the end of systole. LV KEnorm was also increased
at peak diastole in obstructive HCM. Starting immediately after peak LVOT
velocity, LA velocities and KEnorm were significantly elevated in
obstructive patients through the remainder of systole.Discussion/Conclusions
Velocity and KE
analyses are especially effective in characterizing the dynamic, time-varying MR
jet observed in obstructive HCM. High velocity MR jets raise the total kinetic
energy of the LA during systole. Interestingly, these increased LA velocities
are sustained through systole and cease upon opening of the mitral valve. 4D
flow MRI offers novel KE and velocity analyses that can help identify how HCM
patients are expending more energy to compensate and help visualize the 3D deranged
flow patterns. Including these energetic parameters may be useful to detect
significant MR that is underestimated by echo, identify patients at higher risk
of atrial fibrillation, and inform treatment options.Acknowledgements
This work was supported by NIH R01HL 115828.References
1.
Maron, B. J., and M. S.
Maron. "Hypertrophic cardiomyopathy." Lancet 381.9862 (2013):
242-55. Print.
2.
Maron, B. J., et al. Hypertrophic
cardiomyopathy: present and future, with translation into contemporary
cardiovascular medicine. J
Am Coll Cardiol 64.1 (2014): 83-99. Print.
3.
Gersh, B. J., et al.
"2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:
executive summary: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines." J
Am Coll Cardiol 58.25 (2011): 2703-38. Print.
4.
Allen, B. D., et al. "Three-Dimensional Haemodynamics in
Patients with Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy
Assessed by Cardiac Magnetic Resonance." Eur Heart J Cardiovasc Imaging
16.1 (2015): 29-36. Print.
5.
Bock J, Kreher B, Hennig J, Markl M. Optimized
pre-processing of time-resolved 2d and 3d phase contrast mri data. Proceedings
of the 15th Annual Meeting of ISMRM, Berlin, Germany. 2007:3138